Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00126828 | Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 18 | AHS Cancer Control AlbertaOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT01854749 | S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study | completed | Phase 2 | 57 | Fudan UniversityOTHER | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00907569 | Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer | completed | Phase 2 | 2 | AHS Cancer Control AlbertaOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00940069 | TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer(TPEIAL) | completed | Phase 2 | 60 | Hunan Province Tumor HospitalOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00188318 | Hardwins - Squamous Cell Carcinoma Head & Neck (Surgery/RT) | completed | Phase 2 | 169 | University Health Network, TorontoOTHER | 1 | Feb 9, 2016 | clinicaltrials |
| NCT01121939 | Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | completed | Phase 2 | 43 | SCRI Development Innovations, LLCOTHER | 1 | Feb 5, 2016 | clinicaltrials |
| NCT00982592 | Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01260701 | Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 2 | Jan 18, 2016 | clinicaltrials |
| NCT00401609 | G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients(G-Step) | completed | Phase 1 / Phase 2 | 85 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT01533181 | Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 2 | Jan 14, 2016 | clinicaltrials |
| NCT00324870 | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2016 | clinicaltrials |
| NCT00712790 | Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 35 | Singapore Clinical Research InstituteOTHER | 4 | Jan 6, 2016 | clinicaltrials |
| NCT01099540 | Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor | completed | Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Dec 29, 2015 | clinicaltrials |
| NCT01469598 | Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer | completed | Phase 2 | 24 | Samsung Medical CenterOTHER | 1 | Dec 29, 2015 | clinicaltrials |
| NCT01474642 | Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 64 | Samsung Medical CenterOTHER | 1 | Dec 29, 2015 | clinicaltrials |
| NCT00618982 | Sorafenib Dose Escalation in Renal Cell Carcinoma | completed | Phase 2 | 83 | BayerINDUSTRY | 5 | Dec 24, 2015 | clinicaltrials |
| NCT00454142 | Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2015 | clinicaltrials |
| NCT00480389 | Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal | completed | Phase 2 | 19 | University Health Network, TorontoOTHER | 1 | Dec 9, 2015 | clinicaltrials |
| NCT00089180 | T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT01232296 | A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 4, 2015 | clinicaltrials |
| NCT00807300 | Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma(CEAL) | completed | Phase 2 | 77 | University of MagdeburgOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT02008929 | to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)(MG4101) | completed | Phase 2 | 5 | Samsung Medical CenterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00059787 | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Dec 1, 2015 | clinicaltrials |
| NCT00610129 | Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) | completed | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00057863 | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2015 | clinicaltrials |
| NCT00275028 | AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01898065 | Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer(HYPOXProstat) | completed | Phase 2 | 20 | Institut Cancerologie de l'OuestOTHER | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01677455 | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer(Enchant) | completed | Phase 2 | 51 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Nov 5, 2015 | clinicaltrials |
| NCT01932580 | Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma | completed | Phase 2 | 10 | McGill UniversityOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00524498 | A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma | completed | Phase 2 | 60 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 15, 2015 | clinicaltrials |
| NCT01703910 | Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic | completed | Phase 2 | 29 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Oct 9, 2015 | clinicaltrials |
| NCT01713296 | Pazopanib in Relapsed and Refractory Small Cell Lung Cancer | completed | Phase 2 | 58 | Hellenic Oncology Research GroupOTHER | 1 | Oct 8, 2015 | clinicaltrials |
| NCT02061631 | Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck(DECIDE) | completed | Phase 2 | 35 | SanofiINDUSTRY | 1 | Oct 8, 2015 | clinicaltrials |
| NCT00395252 | Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer(ATIP) | completed | Phase 2 | 76 | Carmen Schade-BrittingerOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2015 | clinicaltrials |
| NCT01026792 | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2015 | clinicaltrials |
| NCT01192204 | Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention | completed | Phase 1 / Phase 2 | 41 | Ohio State UniversityOTHER | 1 | Aug 14, 2015 | clinicaltrials |
| NCT02002312 | Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer | completed | Phase 2 | 14 | Radboud University Medical CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00978211 | DOTA-TOC in Metastasized Neuroendocrine Tumors | completed | Phase 2 | 1,499 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 7, 2015 | clinicaltrials |
| NCT00873119 | Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary | completed | Phase 2 | 89 | Valerio TherapeuticsINDUSTRY | 4 | Jul 28, 2015 | clinicaltrials |
| NCT00100841 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00609934 | Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone | completed | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00420888 | ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 526 | Active Biotech ABINDUSTRY | 5 | Jul 22, 2015 | clinicaltrials |
| NCT00952731 | 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ | completed | Phase 2 | 27 | Northwestern UniversityOTHER | 1 | Jul 21, 2015 | clinicaltrials |
| NCT00365391 | Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2015 | clinicaltrials |
| NCT00126490 | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT01093222 | Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT00854620 | Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer | completed | Phase 2 | 9 | Stanford UniversityOTHER | 1 | Jun 19, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Feb 24, 2016source: clinicaltrials